News for RedHill Biopharma Stock (RDHL)

RedHill Biopharma Significantly Extends Unrestricted Commercial Coverage for Talicia® with OptumRx

PRNewsWire • 07/20/21

RedHill Biopharma completes treatment and follow-up in the 475-patient global Phase 2/3 COVID-19 study with opaganib

Proactive Investors • 07/19/21

RedHill Biopharma Ltd Announces RedHill Biopharma Announces Last Patient Out

Accesswire • 07/19/21

RedHill Biopharma Announces Last Patient Out for Phase 2/3 COVID-19 Study of Oral Opaganib

PRNewsWire • 07/19/21

RedHill Biopharma's Movantik® Added as Unrestricted Preferred Brand To A Major National Commercial Formulary Serving over 30 Million Americans

PRNewsWire • 07/13/21

RedHill Biopharma reports preliminary results from new preclinical study showing potent inhibition of COVID-19 variants by opaganib

Proactive Investors • 06/28/21

RedHill Biopharma's Opaganib Inhibits COVID-19 Variants in Preclinical Study

PRNewsWire • 06/28/21

RedHill Biopharma presents positive Phase 2 data for oral opaganib in hospitalized patients with COVID-19 at World Microbe Forum

Proactive Investors • 06/22/21

RedHill Biopharma Announces Presentation of Positive Oral Opaganib Phase 2 Data in COVID-19

PRNewsWire • 06/21/21

3 Top Biotech Picks for June

The Motley Fool • 06/19/21

RedHill Biopharma to Present at the BIO Digital International Convention

PRNewsWire • 06/09/21

RedHill completes enrollment in the global Phase 2/3 severe COVID-19 study with oral opaganib

Proactive Investors • 06/08/21

RedHill Biopharma Completes Enrollment of Oral Opaganib Phase 2/3 COVID-19 Study

PRNewsWire • 06/07/21

RedHill Biopharma highlights strong end to first-quarter and almost 100% enrollment in opaganib's Phase 2/3 study for COVID-19

Proactive Investors • 06/01/21

RedHill Biopharma Ltd.'s (RDHL) CEO Dror Ben-Asher on Q1 2021 Results - Earnings Call Transcript

Seeking Alpha • 05/27/21

Strength Seen in Redhill Biopharma Ltd. (RDHL): Can Its 5.4% Jump Turn into More Strength?

Zacks Investment Research • 05/27/21

Redhill Biopharma: Q1 Earnings Insights

Benzinga • 05/27/21

RedHill Biopharma Reports First Quarter 2021 Financial Results and Operational Highlights

PRNewsWire • 05/27/21

RedHill Biopharma receives two US Patent and Trademark Office Allowances for its oral pills for COVID-19, opaganib and RHB-10

Proactive Investors • 05/26/21

Earnings Outlook for Redhill Biopharma

Benzinga • 05/26/21

RedHill Biopharma Receives Allowances for U.S. Patent Applications Covering Opaganib and RHB-107 for COVID-19

PRNewsWire • 05/26/21

RedHill's Novel Late-Stage Pills Hold Promise Against COVID-19 and its Variants

Benzinga • 05/25/21

RedHill Biopharma Presents Analyses of Movantik Onset of Action and Symptom Improvement at DDW 2021

PRNewsWire • 05/24/21

RedHill Biopharma Presents a New Travelers' Diarrhea Clinical Severity Classification Tool and its Use in Aemcolo Efficacy Analysis at DDW 2021

PRNewsWire • 05/21/21

RedHill Biopharma to Host First Quarter 2021 Financial Results and Operational Highlights Webcast on May 27, 2021

PRNewsWire • 05/20/21